Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab ...

Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

In the past week, bluebird bio named new leaders after its acquisition, Dyne secured a debt deal and ProFound Therapeutics ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

ProFound Therapeutics, a company pioneering the expanded human proteome to develop medicines, has announced a four-year ...

Cofounder James Cadwallader and Dylan Babbs started their AI SEO startup Profound last year when the duo realized they were doing all their research on AI search engines like Perplexity. For many ...

Organizations that delay systematic AI deployment risk being left behind by competitors who have already mastered the transition from experimentation to execution.

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.